[
    {
        "section": "1.1 The initial scope of the Alliance will consist of the Studies described in Exhibit I, the details of which are to be mutually agreed upon by the JSC from time to time in accordance with Sections 1.5 - 1.8 below). The Studies and/or the scope of the Alliance may be replaced and/or changed as agreed upon by the JSC. <*$p$*>Adaptimmune shall have responsibility for IND filing, however, MD Anderson will handle all monitoring responsibilities.<*$p$*> The Alliance Funding (defined in Section 1.3 below) will cover enrollment of a minimum of *** Clinical Study subjects into Clinical Studies (with Clinical Studies in this context excluding any screening Study or long term follow-up Study) (\"Minimum Patient Numbers\").",
        "explanation": "The original text assigns IND filing responsibility to Adaptimmune and monitoring responsibilities to MD Anderson. The modified text assigns both IND filing and monitoring responsibilities to Adaptimmune. This creates an inconsistency in responsibility, impacting regulatory compliance and data integrity.",
        "location": "Section 1.1",
        "category": 3,
        "location_match": true,
        "text_match": false
    },
    {
        "section": "1.1 The initial scope of the Alliance will consist of the Studies described in Exhibit I, the details of which are to be mutually agreed upon by the JSC from time to time in accordance with Sections 1.5 - 1.8 below). The Studies and/or the scope of the Alliance may be replaced and/or changed as agreed upon by the JSC. <*$p$*>Adaptimmune shall have responsibility for IND filing, however, MD Anderson will handle all monitoring responsibilities.<*$p$*> The Alliance Funding (defined in Section 1.3 below) will cover enrollment of a minimum of *** Clinical Study subjects into Clinical Studies (with Clinical Studies in this context excluding any screening Study or long term follow-up Study) (\"Minimum Patient Numbers\").",
        "explanation": "The modified text removes the caveat that MD Anderson is responsible for monitoring responsibilities. This omission creates an in-text contradiction because the contract now lacks clarity on which party bears the responsibility of monitoring. This lack of clarity could affect patient safety and data reliability, leading to disputes.",
        "location": "Section 1.1",
        "category": 7,
        "location_match": true,
        "text_match": false
    },
    {
        "section": "2.9 <*$p$*>MD Anderson will promptly notify Adaptimmune upon identifying any aspect of a Protocol, including information discovered during site monitoring visits, or Study results that may adversely affect the safety, well-being, or medical care of the Study subjects, or that may affect the willingness of Study subjects to continue participation in a Study, influence the conduct of the Study, or that may alter the IRB's approval to continue the Study. Adaptimmune is solely responsible for notifying MD Anderson of data results discovered from Adaptimmune's monitoring visits only.<*$p$*> MD Anderson will promptly notify the IRB of any such events.",
        "explanation": "The original text requires MD Anderson and Adaptimmune to promptly notify each other regarding aspects of the protocol, site monitoring visits, or study results that may affect patient safety, willingness to continue the study, influence the conduct of the study, or alter the IRB's approval to continue the study. The modified text now puts the onus solely on Adaptimmune to notify MD Anderson of data results discovered from Adaptimmune's monitoring visits only. This creates an in-text contradiction because it limits the reciprocal nature of data result notifications, affecting the willingness of study subjects to continue the study or altering the IRB's approval to continue the study.",
        "location": "Section 2.9",
        "category": 3,
        "location_match": false,
        "text_match": false
    },
    {
        "section": "2.9 <*$p$*>MD Anderson will promptly notify Adaptimmune upon identifying any aspect of a Protocol, including information discovered during site monitoring visits, or Study results that may adversely affect the safety, well-being, or medical care of the Study subjects, or that may affect the willingness of Study subjects to continue participation in a Study, influence the conduct of the Study, or that may alter the IRB's approval to continue the Study. Adaptimmune is solely responsible for notifying MD Anderson of data results discovered from Adaptimmune's monitoring visits only.<*$p$*> MD Anderson will promptly notify the IRB of any such events.",
        "explanation": "The original text makes both parties liable to notify each other on any aspect of the protocol that is discovered during site monitoring visits, or study results that may have adverse affects. The modified text states that only Adaptimmune is responsible for notifying MD Anderson of data results. There is an omission on the part of MD Anderson to notify Adaptimmune. This will lead to an in-text contradiction.",
        "location": "Section 2.9",
        "category": 7,
        "location_match": false,
        "text_match": false
    },
    {
        "section": "8.3 A Party may terminate a Study Order: (a) if the other Party commits a material breach of this Agreement or the Study Order and fails to cure such breach within thirty (30) days of receiving notice from the non-breaching Party of such breach; or (b) in the case of any Clinical Studies, due to health and safety concerns related to the Study Drug or procedures in the Study (including regulatory holds due to the health and safety of the Study Subjects); or (c) in the case of MD Anderson and in relation to any Clinical Studies, where IRB requests termination of any Study; or (d) in the case of Adaptimmune, *** set out in Section 1.2 above. <*$p$*>The Parties agree that any termination of a Study Order shall allow for: (i) the wind down of the Study to ensure the safety of Study subjects; and (ii) MD Anderson's final reconciliation of Data related to the Study. The final reconciliation of Data is Adaptimmune's responsibility.<*$p$*>",
        "explanation": "The original text states that any termination of a Study Order shall allow for MD Anderson's final reconciliation of Data related to the Study in addition to Adaptimmune's final monitoring visit. The modified text now shifts the responsibility of final reconciliation of Data to Adaptimmune. The shift from MD Anderson to Adaptimmune for final reconciliation creates an in-text contradiction because it alters the obligations of each party upon termination.",
        "location": "Section 8.3",
        "category": 3,
        "location_match": false,
        "text_match": false
    },
    {
        "section": "8.3 A Party may terminate a Study Order: (a) if the other Party commits a material breach of this Agreement or the Study Order and fails to cure such breach within thirty (30) days of receiving notice from the non-breaching Party of such breach; or (b) in the case of any Clinical Studies, due to health and safety concerns related to the Study Drug or procedures in the Study (including regulatory holds due to the health and safety of the Study Subjects); or (c) in the case of MD Anderson and in relation to any Clinical Studies, where IRB requests termination of any Study; or (d) in the case of Adaptimmune, *** set out in Section 1.2 above. <*$p$*>The Parties agree that any termination of a Study Order shall allow for: (i) the wind down of the Study to ensure the safety of Study subjects; and (ii) MD Anderson's final reconciliation of Data related to the Study. The final reconciliation of Data is Adaptimmune's responsibility.<*$p$*>",
        "explanation": "The shift of responsibilities related to reconcilation of data is removed from MD Anderson to Adaptimmune. There is an omission on the original text where it previously mentioned MD Anderson was responsible for reconcilation of data. This will create an in-text contradiction.",
        "location": "Section 8.3",
        "category": 7,
        "location_match": false,
        "text_match": false
    }
]